

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL

OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) None	Entity Type
0001567264	Intensity Therapeutics,	© Corporation
Name of Issuer	LLC	C Limited Partnership
Intensity Therapeutics, Inc.		C Limited Liability Company
Jurisdiction of Incorporation/Organization		C General Partnership
DELAWARE		C Business Trust
Year of Incorporation/Organization	on	O _{Other}
C Over Five Years Ago		
Within Last Five Years (Specify Year)	2012	
C Yet to Be Formed		

2. Principal Place of Business and Contact Information				
Name of Issuer				
Intensity Therapeutics, Inc.				
Street Address 1		Street Address 2		
40 RICHARDS AVENUE		3RD FLOOR		
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer	
NORWALK	CONNECTICUT	06854	914-329-6571	

3. Related Persons		
Last Name	First Name	Middle Name
Bender Street Address 1	Street Address 2	Н.
40 Richards Avenue, 3rd Floor		
City Norwalk	State/Province/Country CONNECTICUT	ZIP/Postal Code
Relationship: Execu	tive Officer Director	Promoter
Clarification of Response (if Necessar	y)	1

4. Industry Group

C B	Agriculture Sanking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial Services Susiness Services Georgy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy	Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate	C Restaurants Technology C Computers C Telecommunications C Other Technology Travel C Airlines & Airports C Lodging & Conventions C Tourism & Travel Services C Other Travel C Other
F	loouer Ci-c		
	ssuer Size		
Reve	nue Range No Revenues	Aggregate Net Asset No Aggregate	_
7000			te Net Asset Value
0	\$1 - \$1,000,000	C \$1 - \$5,000,0 C \$5,000,001 -	
0	\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000		- \$50,000,000
0	\$25,000,001 - \$100,000,000	N=0	- \$100,000,000
0	Over \$100,000,000	Over \$100,00	
•	Decline to Disclose	C Decline to Di	
0	Not Applicable	C Not Applical	
apı	Federal Exemption(s) a oly) Rule 504(b)(1) (not (i), (ii)	Rule 505 Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Sec	
7.	Type of Filing		
	New Notice Date of First Sale Amendment	2013-01-05	First Sale Yet to Occur
	Duration of Offering the Issuer intend this offering to last me	ore than one year?	O Yes © No
П	Interests	fered (select all that quity	apply)

П	Option, Warrant or Other Right to Mineral Property Securities Acquire Another Security
V	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)
10	Business Combination Transaction
Is th	is offering being made in connection with a business combination
	saction, such as a merger, acquisition or exchange offer?
	menton of recipouse (if recessing)
11	. Minimum Investment
Min inve	imum investment accepted from any outside stor
40	
	. Sales Compensation Recipient CRD Number None
Rec	ipient Recipient CRD Number None
(As:	sociated) Broker or Dealer None (Associated) Broker or Dealer CRD None
	Number Number
Str	reet Address 1 Street Address 2
City	y State/Province/Country ZIP/Postal Code
State	e(s) of Solicitation
40	Official and Color American
13	3. Offering and Sales Amounts
Tota	al Offering Amount \$ 1000000 USD Indefinite
Tota	al Amount Sold \$ 175000 USD
Tota Sold	al Remaining to be \$\begin{array}{ c c c c c c c c c c c c c c c c c c c
Clar	rification of Response (if Necessary)
pu	fering of convertible notes, common stock, and warrants to rchase common stock (including underlying shares to be issued on conversion of notes or exercise of warrants).
14	I. Investors
	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Sales Commissions	\$ 0	USD	Estimate
Finders' Fees	\$ 0	USD	Estimate
Clarification of Response (if Necessar	у)		

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0	USD	Estimate
	<u> </u>	

Signature and Submission

Clarification of Response (if Necessary)

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Intensity Therapeutics, Inc.	/s/ Lewis H. Bender	Lewis H. Bender	President, Treasurer and Secretary	2013-01-18